VACCINE ENHANCEMENTS

Researchers at the Tulane National Primate Research Center found that a vaccine currently being developed induces a robust and long-lasting immune response against SARS-CoV-2 in nonhuman primates, similar to the protection provided by the Moderna vaccine. The study evaluated five different adjuvants, or ingredients added to vaccines, to determine which provides the most protection from the virus in nonhuman primates. Results indicated that all five adjuvants produced strong immune responses after two consecutive immunizations and induced considerable neutralizing antibodies and CD4 cells, the cells responsible for triggering the body’s response to infection.

Horizontal thumbnail